Navigation Links
ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium
Date:1/22/2009

patients who responded to ecabet sodium was greater than that seen in the trials that led to the approval of the only currently approved product on the market for dry eye disease. Further, this trend in increased Schirmer Test score was seen as early as day 22 of treatment and continued to trend upwards through day 43. Adverse events were uncommon and similar between the treatment and placebo groups, and there were no serious ocular or systemic adverse events.

Another important finding in this trial was that patients with more severe disease as measured by the Anesthetized Schirmer Test, TFBUT and specific staining attributes were more likely to respond to ecabet sodium than placebo. Thus, in future Phase III trials, these specific attributes can be used for screening of patients who would be most likely to benefit from treatment with ecabet sodium.

About Ecabet Sodium

ISTA acquired U.S. rights to ecabet sodium for the treatment of dry eye syndrome from Senju Pharmaceuticals Co., Ltd., in November of 2004. Ecabet sodium is already marketed in Japan as an oral agent for gastric ulcers and gastritis by Mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku Co., Ltd.) as an originator of ecabet sodium.

Ecabet sodium represents a new class of molecules that increase the quantity of mucin produced by conjunctival goblet cells and corneal epithelia. Mucin is a glycoprotein component of tear film that lubricates while retarding moisture loss from tear evaporation.

About ISTA Pharmaceuticals

ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA's products and product candidates addressing the $4.7 billion U.S. prescription ophthalmic industry include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company currently markets three products and is developing a strong product pipeline to fuel future growth and market share, thereby continui
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. ISTA Pharmaceuticals New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration
2. Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
3. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
4. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
5. Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia
6. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
7. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
8. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
9. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... 17 The Make-A-Wish Foundation announced today ... from the LATISSE ® ... Allergan, Inc. ,, Based on the tradition of ... come true, the campaign launched earlier this year ... Foundation by leveraging the excitement around the availability ...
(Date:12/16/2009)... Dec. 17 Cell Therapeutics, Inc. ... that on February 10, 2010 the U.S. ... Committee (ODAC) will review the New Drug ... of relapsed/refractory aggressive non-Hodgkin,s lymphoma (NHL). ODAC ... evaluates data concerning the efficacy and safety ...
(Date:12/16/2009)... , Dec. 16 MedSolutions ( ... management services, today commended two new studies highlighting ... scans and other diagnostic imaging tests. ,, ... proper diagnosis and treatment," said Gregg Allen, M.D., ... studies offer more compelling evidence that stricter quality ...
Breaking Medicine Technology:The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign 2The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign 3The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign 4The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign 5Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 2Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 3Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 4MedSolutions Applauds Renewed Focus on the Dangers of Radiation Exposure 2MedSolutions Applauds Renewed Focus on the Dangers of Radiation Exposure 3American Investors Highlight Successes in Eastern Germany 48753 1American Investors Highlight Successes in Eastern Germany 48753 2Healthcare Travel Congress 2009 3A Experts Worldwide Convene in Singapore For Regional Conference on Medical Tourism 48752 1Healthcare Travel Congress 2009 3A Experts Worldwide Convene in Singapore For Regional Conference on Medical Tourism 48752 2Healthcare Travel Congress 2009 3A Experts Worldwide Convene in Singapore For Regional Conference on Medical Tourism 48752 3Tasty Baking Company Supports the Fight Against Childhood Cancer Through Partnership with Alexs Lemonade Stand Foundation 48750 1Tasty Baking Company Supports the Fight Against Childhood Cancer Through Partnership with Alexs Lemonade Stand Foundation 48750 2Tasty Baking Company Supports the Fight Against Childhood Cancer Through Partnership with Alexs Lemonade Stand Foundation 48750 3
... BIRMINGHAM, Ala., April 03, 2007 /PRNewswire/ -- Southern,Research ... research in the areas of preclinical drug,discovery and ... delivering one oral presentation and 10 poster,presentations at ... Meeting, April 14-18 in Los Angeles, Calif. , ...
... Absorption of Fat and Protein during Clinical ... 04, 2007 /PRNewswire/ --,Eurand, a global specialty ... III clinical trials on its lead product,candidate, ... Pancreatic Insufficiency (EPI). The US Food and ...
Other Medicine Technology:Southern Research Institute to Present at the 2007 American,Association For Cancer Research Annual Meeting 2Southern Research Institute to Present at the 2007 American,Association For Cancer Research Annual Meeting 3Eurand Announces Positive Phase III Clinical Study Results 2Eurand Announces Positive Phase III Clinical Study Results 3Eurand Announces Positive Phase III Clinical Study Results 4Eurand Announces Positive Phase III Clinical Study Results 5
(Date:12/17/2009)... "Comprehensive Respect for Life" in Majority Leader,s Revisions ... ,, WASHINGTON, Dec. 17 Americans United ... a letter today to Senate Majority Leader Harry ... the Majority Leader,s revisions to a bill - ... urges Senator Reid to include "specific language that ...
(Date:12/17/2009)... , , THURSDAY, Dec. 17 (HealthDay News) -- In a ... of the fish oil fatty acids that are good ... fats and the molecules that help them form clots. ... response has some potentially negative effects in comparison to ... Lindsay E. Robinson, an associate professor of nutrition at ...
(Date:12/17/2009)... Force pediatric surgeon Dr. Chris Coppola scrubbed in to perform surgery ... the swollen right lobe of his brain. Now, having returned from ... to provide medical aid to children living in Kabul’s largest internally ... ... -- , , ,During his first night on call in ...
(Date:12/17/2009)... information using virtually any smart phone , ... ... Inc., the world’s most trusted source for medical information delivered ... clinical decision application on the Google Android operating system. Skyscape’s ... devices, making the ability for medical professionals to download the ...
(Date:12/17/2009)... NEW YORK, Dec. 17 ... research report is available in its ... A strategic assessment of the competitive ... of the highest priority management responsibilities, ... growth and profitability. Timely and factual ...
Breaking Medicine News(10 mins):Health News:Pro-Life Leader Sends Urgent Letter to Senator Reid 2Health News:Could Omega-3s Boost Blood Fat Levels? 2Health News:U.S. Pediatric Surgeon Heals War's Youngest Victims in Iraq, Donates Medical Aid to Displaced Children in Kabul, Afghanistan 2Health News:U.S. Pediatric Surgeon Heals War's Youngest Victims in Iraq, Donates Medical Aid to Displaced Children in Kabul, Afghanistan 3Health News:Skyscape Offers Medical Professionals Real Time Clinical Decision Application on Google Android 2Health News:Skyscape Offers Medical Professionals Real Time Clinical Decision Application on Google Android 3Health News:Skyscape Offers Medical Professionals Real Time Clinical Decision Application on Google Android 4Health News:Reportlinker Adds Top Ten World's Leading Life Science Intermediates Companies 2
... Contrary to prevailing assumptions, children are more vulnerable ... age of 6 than they are in early childhood, ... to be presented May 4 at the annual meeting ... we typically worry about protecting toddlers from lead exposure, ...
... surprisingly low-level knowledge of typical infant development and ... emotional growth, according research from the University of ... false parenting assumptions can not only impair parent-child ... stimulation, will be presented Sunday, May 4, at ...
... for acid reflux, urinary incontinence ,slow down, seniors, studies ... Two new studies show that anticholinergics, a commonly prescribed ... down" in their daily physical activities. , The two ... Medicine support findings released a few weeks ago that ...
... facing the possibility of hysterectomy may now choose ... to Yale professor Aydin Arici, M.D., who will ... the American College of Obstetricians and Gynecologists (ACOG) ... Louisiana. , Arici will chair the two-day ...
... trial , , FRIDAY, May 2 (HealthDay News) -- The ... low levels of carbohydrates and controlled protein intake, helps ... a new study finds. , The trial is the ... diet -- widely used since the 1920s -- is ...
... most often , , SATURDAY, May 3 (HealthDay News) ... or more cough and cold medications during a given ... While cough and cold medications for children are widely ... used had not been scientifically studied. This new finding, ...
Other Medicine News:Health News:Children more vulnerable to harmful effects of lead 2Health News:Nearly one-third of US parents don't know what to expect of infants 2Health News:Common Medications Could Cause Physical Impairment in the Elderly 2Health News:Treatment advances for fibroids, menopause 2Health News:Special Diet Can Ease Epileptic Seizures in Kids 2Health News:10% of U.S. Kids Using Cough Medicine Every Week 2
... you need quick, accurate, convenient, and cost-effective ... VITROS DT60 II Chemistry System. This easy-to-use ... back-up laboratory testing requirements. And it helps ... better patient outcomes, reduced overall costs, and ...
... provides power and efficiency to ... volume testing facilities. With fast ... results per hour, the Vitros ... the full complement of Vitros ...
... Abbott entered the Therapeutic Drug Monitoring ... the TDx. Still in use today, this ... Polarization Immunoassay) to measure serum drug concentration ... the treatment of different diseases, often exhibit ...
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
Medicine Products: